Further, the eloquent work of Bellail and colleagues19 definitively demonstrated that cyclin dependent kinase (CDK)6 is modified by SUMO-1 in GBM, and that CDK6 SUMOylation stabilizes the protein and drives the cell cycle, leading to cancer development/progression via inhibition of its ubiquitin-mediated degradation. The gene discussed is CDK6; the disease is glioblastoma.